(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.14%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms...
Stats | |
---|---|
Šios dienos apimtis | 758 797 |
Vidutinė apimtis | 980 816 |
Rinkos kapitalizacija | 7.38B |
EPS | INR0 ( 2024-02-12 ) |
Kita pelno data | ( INR0 ) 2024-05-27 |
Last Dividend | INR1.000 ( 2011-09-20 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 17.00 |
ATR14 | INR0.136 (0.11%) |
Tūris Koreliacija
Ind-Swift Laboratories Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PVP.NS | 0.827 |
ICICIPHARM.NS | 0.813 |
KIMS.NS | 0.811 |
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Ind-Swift Laboratories Koreliacija - Valiuta/Žaliavos
Ind-Swift Laboratories Finansinės ataskaitos
Annual | 2022 |
Pajamos: | INR12.07B |
Bruto pelnas: | INR5.52B (45.70 %) |
EPS: | INR8.06 |
FY | 2022 |
Pajamos: | INR12.07B |
Bruto pelnas: | INR5.52B (45.70 %) |
EPS: | INR8.06 |
FY | 2022 |
Pajamos: | INR10.39B |
Bruto pelnas: | INR4.28B (41.20 %) |
EPS: | INR-0.360 |
FY | 2021 |
Pajamos: | INR8.91B |
Bruto pelnas: | INR3.61B (40.51 %) |
EPS: | INR-0.530 |
Financial Reports:
No articles found.
Ind-Swift Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR1.000 | 2004-09-23 |
Last Dividend | INR1.000 | 2011-09-20 |
Next Dividend | INR0 | N/A |
Payout Date | 2011-10-26 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | INR9.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.37 | -- |
Div. Sustainability Score | 1.760 | |
Div.Growth Potential Score | 3.47 | |
Div. Directional Score | 2.62 | -- |
Year | Amount | Yield |
---|---|---|
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TOUCHWOOD.NS | Dividend Junior | 2023-09-22 | Annually | 6 | 0.15% | |
PGIL.NS | Dividend Junior | 2023-09-01 | Annually | 17 | 1.08% | |
JINDALSAW.NS | Dividend Junior | 2023-06-13 | Annually | 22 | 1.62% | |
DEEPAKNTR.NS | Dividend Junior | 2023-07-27 | Annually | 14 | 0.25% | |
SKMEGGPROD.NS | Dividend Junior | 2023-08-30 | Sporadic | 21 | 0.95% | |
MGEL.NS | Dividend Junior | 2023-08-08 | Annually | 5 | 0.59% | |
HARSHA.NS | Dividend Junior | 2023-09-20 | Insufficient data to determine frequency | 2 | 0.09% | |
BDL.NS | Dividend Junior | 2023-09-20 | Semi-Annually | 7 | 1.17% | |
PTC.NS | Dividend Knight | 2023-09-20 | Annually | 21 | 6.06% | |
KDDL.NS | Dividend Junior | 2023-09-22 | Annually | 8 | 0.29% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0362 | 1.500 | 9.28 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0612 | 1.500 | -0.431 | -0.647 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 2.56 | 1.000 | -0.163 | -0.163 | [3 - 30] |
operatingCashFlowPerShareTTM | 16.90 | 2.00 | 4.37 | 8.74 | [0 - 30] |
freeCashFlowPerShareTTM | 16.90 | 2.00 | 1.552 | 3.10 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.476 | 1.000 | 5.40 | 5.40 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.181 | 1.000 | 8.37 | 8.37 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.760 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.09 | 1.000 | 8.37 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0612 | 2.50 | -0.277 | -0.647 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 16.90 | 2.00 | 4.37 | 3.10 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 16.90 | 2.00 | 4.37 | 8.74 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.533 | 1.500 | 9.78 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0838 | 1.000 | -0.406 | 0 | [0.1 - 0.5] |
Total Score | 3.47 |
Ind-Swift Laboratories
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.